STS and lung carcinoma: Likewise, results obtained with other STs inhibitors (SsaI and AL10) showed that inhibition of α2,3-sialylation impaired cell motility, adhesion, and migration through ECM components and cell invasion in ovarian and lung cancer cells [21,28,29].